CoChat

Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Open access
Lee, Bianca J., Boyer, Jacob A., Burnett, G. Leslie, Thottumkara, Arun P., Tibrewal, Nidhi, Wilson, Stacy L., Hsieh, Tientien, Marquez, Abby, Lorenzana, Edward G., Evans, James W., Hulea, Laura, Kiss, Gert, Liu, Hui, Lee, Dong, Larsson, Ola, McLaughlan, Shannon, Topisirovic, Ivan, Wang, Zhengping, Wang, Zhican, Zhao, Yongyuan, Wildes, David, Aggen, James B., Singh, Mallika, Gill, Adrian L., Smith, Jacqueline A. M., Rosen, Neal · 2021 · Nature Chemical Biology
Cited by 82

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The clinical benefits of pan-mTOR active-site inhibitors are limited by toxicity and relief of feedback inhibition of receptor expression. To address these limitations, we designed a series of compounds that selectively inhibit mTORC1 and not mTORC2. These ‘bi-steric inhibitors’ comprise a rapamycin-like core moiety covalently linked to an mTOR active-site inhibitor. Structural modification of these components modulated their affinities for their binding sites on mTOR and the selectivity of the bi-steric compound. mTORC1-selective compounds potently inhibited 4EBP1 phosphorylation and caused regressions of breast cancer xenografts. Inhibition of 4EBP1 phosphorylation was sufficient to block cancer cell growth and was necessary for maximal antitumor activity. At mTORC1-selective doses, these compounds do not alter glucose tolerance, nor do they relieve AKT-dependent feedback inhibition of HER3. Thus, in preclinical models, selective inhibitors of mTORC1 potently inhibit tumor growth while causing less toxicity and receptor reactivation as compared to pan-mTOR inhibitors. Design of a bivalent inhibitor containing an ATP-competitive moiety and rapamycin-modified FRB binding ligand that selectively inhibits mTORC1 results in potent and durable inhibition of 4EBP1 phosphorylation and cell proliferation in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41589-021-00813-7

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 46

  1. Chalhoub, N. & Baker, S. J. PTEN and the PI3-kinase pathway in cancer. Annu Rev. Pathol. 4, 127–150 (2009). · DOI · Paper page
  2. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501 (2002). · DOI · Paper page
  3. Sengupta, S., Peterson, T. R. & Sabatini, D. M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell 40, 310–322 (2010). · DOI · Paper page
  4. Dowling, R. J. et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172–1176 (2010). · DOI · Paper page
  5. Fingar, D. C. et al. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 24, 200–216 (2004). · DOI · Paper page
  6. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the RICTOR-mTOR complex. Science 307, 1098–1101 (2005). · DOI · Paper page
  7. Avdulov, S. et al. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5, 553–563 (2004). · DOI · Paper page
  8. Roux, P. P. & Topisirovic, I. Signaling pathways involved in the regulation of mRNA translation. Mol. Cell Biol. 38, e00070-18 (2018). · DOI · Paper page
  9. Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009). · DOI · Paper page
  10. Choi, J., Chen, J., Schreiber, S. L. & Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239–242 (1996). · DOI · Paper page
  11. Choo, A. Y., Yoon, S. O., Kim, S. G., Roux, P. P. & Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl Acad. Sci. USA 105, 17414–17419 (2008). · DOI · Paper page
  12. Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006). · DOI · Paper page
  13. Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140–151 (2008). · DOI · Paper page
  14. Buti, S., Leonetti, A., Dallatomasina, A. & Bersanelli, M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid. 11, 23–36 (2016). · DOI
  15. Vinayak, S. & Carlson, R. W. mTOR inhibitors in the treatment of breast cancer. Oncol. 27, 38–44 (2013). 46, 48 passim.
  16. Graham, L. et al. A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. Invest. N. Drugs 36, 458–467 (2018). · DOI · Paper page
  17. Powles, T. et al. A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer. Eur. Urol. 69, 450–456 (2016). · DOI
  18. Hagiwara, A. et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 15, 725–738 (2012). · DOI · Paper page
  19. Muranen, T. et al. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21, 227–239 (2012). · DOI · Paper page
  20. Rodrik-Outmezguine, V. S. et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Disco. 1, 248–259 (2011). · DOI · Paper page
  21. Serra, V. et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30, 2547–2557 (2011). · DOI · Paper page
  22. Fan, Q. et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell 31, 424–435 (2017). · DOI · Paper page
  23. Mohr, K. et al. Rational design of dualsteric GPCR ligands: quests and promise. Br. J. Pharmacol. 159, 997–1008 (2010). · DOI · Paper page
  24. Valant, C., Robert Lane, J., Sexton, P. M. & Christopoulos, A. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52, 153–178 (2012). · DOI · Paper page
  25. Yu, K. et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69, 6232–6240 (2009). · DOI · Paper page
  26. Chen, X. et al. Cryo-EM structure of human mTOR complex 2. Cell Res. 28, 518–528 (2018). · DOI
  27. Shi, Y., Yan, H., Frost, P., Gera, J. & Lichtenstein, A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 4, 1533–1540 (2005). · DOI · Paper page
  28. Sun, S. Y. et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 7052–7058 (2005). · DOI · Paper page
  29. Bayle, J. H. et al. Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem. Biol. 13, 99–107 (2006). · DOI · Paper page
  30. Luengo, J. I. et al. Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface. Chem. Biol. 2, 471–481 (1995). · DOI
  31. Reichling, L. J. et al. Pharmacological characterization of purified recombinant mTOR FRB-kinase domain using fluorescence-based assays. J. Biomol. Screen 13, 238–244 (2008). · DOI
  32. Patricelli, M. P. et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 46, 350–358 (2007). · DOI · Paper page
  33. Hsieh, A. C. et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17, 249–261 (2010). · DOI · Paper page
  34. Rong, L. et al. Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA 14, 1318–1327 (2008). · DOI · Paper page
  35. Petroulakis, E. et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 16, 439–446 (2009). · DOI
  36. Masvidal, L., Hulea, L., Furic, L., Topisirovic, I. & Larsson, O. mTOR-sensitive translation: cleared fog reveals more trees. RNA Biol. 14, 1299–1305 (2017). · DOI · Paper page
  37. Gandin, V. et al. nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Res 26, 636–648 (2016). · DOI · Paper page
  38. Larsson, O. et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl Acad. Sci. USA 109, 8977–8982 (2012). · DOI · Paper page
  39. Basu, B. et al. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin. Cancer Res. 21, 3412–3419 (2015). · DOI · Paper page
  40. Steinfeld, T., Mammen, M., Smith, J. A., Wilson, R. D. & Jasper, J. R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol. Pharmacol. 72, 291–302 (2007). · DOI
  41. Gandin, V. et al. Polysome fractionation and analysis of mammalian translatomes on a genome-wide scale. J. Vis. Exp. 2014, 51455 (2014).
  42. Oertlin, C. et al. Generally applicable transcriptome-wide analysis of translation using anota2seq. Nucleic Acids Res. 47, e70 (2019). · DOI · Paper page
  43. Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276–278 (2020). · DOI · Paper page
  44. Ritchie, M. E. et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). · DOI · Paper page
  45. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010). · DOI · Paper page
  46. Lorent, J. et al. Translational offsetting as a mode of estrogen receptor alpha-dependent regulation of gene expression. EMBO J. 38, https://doi.org/10.15252/embj.2018101323 (2019). · DOI · Paper page

Cited by

See all 82

Metadata

Authors
Lee, B. J., Boyer, J. A., Burnett, G. L., Thottumkara, A. P., Tibrewal, N., Wilson, S. L., Hsieh, T., Marquez, A., Lorenzana, E. G., Evans, J. W., Hulea, L., Kiss, G., Liu, H., Lee, D., Larsson, O., McLaughlan, S., Topisirovic, I., Wang, Z., Wang, Z., Zhao, Y., Wildes, D., Aggen, J. B., Singh, M., Gill, A. L., Smith, J. A. M., & Rosen, N.
Venue
Nature Chemical Biology
Published
2021-06-24
Volume
17
Issue
10
Pages
1065-1074
ISSN
  • 1552-4450 (ISSN-L)
  • 1552-4469
OpenAlex
W3177289604
Cited by
82
References
11
FWCI
3.62
Type
journal article
Language
en
Open access
green
Licence
Funders
Breast Cancer Research Foundation (BCRF-20-141)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. https://app.cochat.ai/papers/10.1038/s41589-021-00813-7
The paper
Lee, B. J., Boyer, J. A., Burnett, G. L., Thottumkara, A. P., Tibrewal, N., Wilson, S. L., Hsieh, T., Marquez, A., Lorenzana, E. G., Evans, J. W., Hulea, L., Kiss, G., Liu, H., Lee, D., Larsson, O., McLaughlan, S., Topisirovic, I., Wang, Z., Wang, Z., . . . Rosen, N. (2021). Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth. Nature Chemical Biology. https://doi.org/10.1038/s41589-021-00813-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.